PE20191076A1 - Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismo - Google Patents
Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismoInfo
- Publication number
- PE20191076A1 PE20191076A1 PE2019000529A PE2019000529A PE20191076A1 PE 20191076 A1 PE20191076 A1 PE 20191076A1 PE 2019000529 A PE2019000529 A PE 2019000529A PE 2019000529 A PE2019000529 A PE 2019000529A PE 20191076 A1 PE20191076 A1 PE 20191076A1
- Authority
- PE
- Peru
- Prior art keywords
- cdr
- seq
- same
- functional fragment
- antibody specifically
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 3
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/1039—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Se refiere a un anticuerpo o fragmento funcional del mismo capaz de unirse especificamente a muerte programada-1 (PD-1), comprendiendo una cadena ligera, la cual comprende una CDR de cadena ligera que consiste en CDR-L1, CDR-L2 y CDR-L3 y una cadena pesada, la cual comprende una CDR de cadena pesada que consiste en CDR-H1, CDR-H2 y CDR-H3, donde las secuencias de aminoacidos de la CDR-L1, CDR-L2 y CDR-L3 se exponen respectivamente en las SEQ ID NO:1, 5 y 6, o en las SEQ ID NO:2, 5 y 6 o en las SEQ ID NO:3, 5 y 6 o en las SEQ ID NO:4, 5 y 6. Las secuencias de aminoacidos de las CDR-H1, CDR-H2 y CDR-H3 se exponen en las SEQ ID NO:7, 8 y 9. Tambien se refiere a una molecula de acido nucleico, a una composicion que comprende al anticuerpo o fragmento funcional del mismo y a metodos de preparacion. La presente invencion es util para la prevencion y tratamiento de enfermedades autoinmunitarias, respuestas inmunitarias contra un trasplante, alergias, infecciones, enfermedades neurodegenerativas o tumores
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610827099 | 2016-09-14 | ||
PCT/CN2017/101082 WO2018050027A1 (zh) | 2016-09-14 | 2017-09-08 | 一种能够特异性地结合pd-1的抗体及其功能片段 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20191076A1 true PE20191076A1 (es) | 2019-08-20 |
Family
ID=61619805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2019000529A PE20191076A1 (es) | 2016-09-14 | 2017-09-08 | Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismo |
Country Status (21)
Country | Link |
---|---|
US (1) | US11117967B2 (es) |
EP (1) | EP3514177B1 (es) |
JP (2) | JP7164528B2 (es) |
KR (1) | KR102266788B1 (es) |
CN (1) | CN109952316A (es) |
AU (1) | AU2017328309B2 (es) |
BR (1) | BR112019004995A2 (es) |
CA (1) | CA3036912C (es) |
CL (1) | CL2019000658A1 (es) |
CO (1) | CO2019002369A2 (es) |
DO (1) | DOP2019000064A (es) |
EA (1) | EA201990672A1 (es) |
EC (1) | ECSP19018327A (es) |
IL (1) | IL265333A (es) |
MX (1) | MX2019002969A (es) |
MY (1) | MY189618A (es) |
PE (1) | PE20191076A1 (es) |
PH (1) | PH12019500552A1 (es) |
TN (1) | TN2019000081A1 (es) |
WO (1) | WO2018050027A1 (es) |
ZA (1) | ZA201902120B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018008891A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
KR102317574B1 (ko) | 2015-11-18 | 2021-10-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
MX2019002969A (es) * | 2016-09-14 | 2019-09-18 | Beijing hanmi pharm co ltd | Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismo. |
EP3661954B1 (en) | 2017-08-03 | 2022-02-09 | Amgen Inc. | Interleukin-21 muteins and methods of treatment |
CR20210319A (es) | 2018-01-12 | 2021-07-27 | Amgen Inc | ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330) |
US11408840B2 (en) * | 2018-06-28 | 2022-08-09 | Just-Evotec Biologics, Inc. | High throughput interrogation of physiochemical properties of a protein |
WO2022148414A1 (zh) * | 2021-01-08 | 2022-07-14 | 北京韩美药品有限公司 | 特异性结合pd-l1的抗体及其抗原结合片段 |
WO2022242738A1 (en) * | 2021-05-20 | 2022-11-24 | Shanghai Junshi Biosciences Co., Ltd. | Use of anti-pd-1 antibody in combination with chemotherapy in treating esophageal cancer |
CN116687933A (zh) * | 2022-02-28 | 2023-09-05 | 中国科学院上海药物研究所 | 甲氨蝶呤及其药物组合物在肿瘤免疫治疗中的用途 |
WO2024054418A1 (en) * | 2022-09-08 | 2024-03-14 | Cugene Inc. | Sequence optimization of a pd1 blocking antibody |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1210428E (pt) * | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
CR20160319A (es) * | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
US9067998B1 (en) * | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
NZ728688A (en) * | 2014-07-22 | 2023-06-30 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
CN104479020B (zh) * | 2014-12-26 | 2019-08-02 | 上海复宏汉霖生物技术股份有限公司 | 一种抗pd-1人源抗体 |
CN112263677A (zh) * | 2015-02-26 | 2021-01-26 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
CN105061597B (zh) | 2015-06-09 | 2016-04-27 | 北京东方百泰生物科技有限公司 | 一种抗pd-1的单克隆抗体及其获得方法 |
CN105175544B (zh) * | 2015-10-20 | 2021-04-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗pd-1人源化单克隆抗体及其应用 |
CN105566496B (zh) * | 2015-11-26 | 2019-04-02 | 大庆东竺明生物技术有限公司 | 阻断人程序性死亡因子1(pd-1)功能的单克隆抗体及其编码基因和应用 |
MX2019002969A (es) * | 2016-09-14 | 2019-09-18 | Beijing hanmi pharm co ltd | Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismo. |
-
2017
- 2017-09-08 MX MX2019002969A patent/MX2019002969A/es unknown
- 2017-09-08 TN TNP/2019/000081A patent/TN2019000081A1/en unknown
- 2017-09-08 CN CN201780056736.2A patent/CN109952316A/zh not_active Withdrawn
- 2017-09-08 WO PCT/CN2017/101082 patent/WO2018050027A1/zh unknown
- 2017-09-08 KR KR1020197010360A patent/KR102266788B1/ko active IP Right Grant
- 2017-09-08 EP EP17850229.0A patent/EP3514177B1/en active Active
- 2017-09-08 AU AU2017328309A patent/AU2017328309B2/en active Active
- 2017-09-08 MY MYPI2019001351A patent/MY189618A/en unknown
- 2017-09-08 CA CA3036912A patent/CA3036912C/en active Active
- 2017-09-08 US US16/332,880 patent/US11117967B2/en active Active
- 2017-09-08 JP JP2019535431A patent/JP7164528B2/ja active Active
- 2017-09-08 EA EA201990672A patent/EA201990672A1/ru unknown
- 2017-09-08 BR BR112019004995A patent/BR112019004995A2/pt active Search and Examination
- 2017-09-08 PE PE2019000529A patent/PE20191076A1/es unknown
-
2019
- 2019-03-13 IL IL265333A patent/IL265333A/en unknown
- 2019-03-14 EC ECSENADI201918327A patent/ECSP19018327A/es unknown
- 2019-03-14 PH PH12019500552A patent/PH12019500552A1/en unknown
- 2019-03-14 CL CL2019000658A patent/CL2019000658A1/es unknown
- 2019-03-14 DO DO2019000064A patent/DOP2019000064A/es unknown
- 2019-03-14 CO CONC2019/0002369A patent/CO2019002369A2/es unknown
- 2019-04-04 ZA ZA2019/02120A patent/ZA201902120B/en unknown
-
2021
- 2021-05-20 JP JP2021085449A patent/JP2021121216A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102266788B1 (ko) | 2021-06-22 |
TN2019000081A1 (en) | 2020-07-15 |
CA3036912C (en) | 2022-06-07 |
CO2019002369A2 (es) | 2019-05-10 |
EP3514177B1 (en) | 2023-07-26 |
AU2017328309B2 (en) | 2020-10-15 |
KR20190047013A (ko) | 2019-05-07 |
ZA201902120B (en) | 2022-07-27 |
MX2019002969A (es) | 2019-09-18 |
JP2019532669A (ja) | 2019-11-14 |
WO2018050027A1 (zh) | 2018-03-22 |
CA3036912A1 (en) | 2018-03-22 |
AU2017328309A1 (en) | 2019-04-18 |
US11117967B2 (en) | 2021-09-14 |
DOP2019000064A (es) | 2019-05-31 |
MY189618A (en) | 2022-02-21 |
JP2021121216A (ja) | 2021-08-26 |
CL2019000658A1 (es) | 2019-07-19 |
CN109952316A (zh) | 2019-06-28 |
PH12019500552A1 (en) | 2019-12-02 |
EA201990672A1 (ru) | 2019-08-30 |
EP3514177A1 (en) | 2019-07-24 |
EP3514177A4 (en) | 2020-05-13 |
ECSP19018327A (es) | 2019-05-31 |
NZ752184A (en) | 2021-10-29 |
IL265333A (en) | 2019-05-30 |
BR112019004995A2 (pt) | 2019-06-04 |
JP7164528B2 (ja) | 2022-11-01 |
US20190367615A1 (en) | 2019-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20191076A1 (es) | Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismo | |
CO2018004532A2 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
PE20191075A1 (es) | Anticuerpo que se une especificamente a il-17a y fragmento funcional del mismo | |
CY1123212T1 (el) | Συνθεσεις για την αναστολη της ενεργοποιησης του masp-2 εξαρτωμενου συμπληρωματος | |
PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
PE20190212A1 (es) | Anticuerpos anti_ige | |
PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
MY190771A (en) | Anti-pd-l1 antibodies and uses thereof | |
AR080501A1 (es) | Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1) | |
PE20190737A1 (es) | Anticuerpos anti-cd27 | |
EA034770B8 (ru) | Человеческие антитела к pd-1 | |
AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
MX2019005117A (es) | Anticuerpos dirigidos contra la muerte programada 1 (pd-1). | |
PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
NZ727024A (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
PE20181051A1 (es) | Anticuerpo anti-epha4 | |
EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
WO2014179664A3 (en) | Antibodies directed against programmed death-1 (pd-1) | |
NZ706377A (en) | Il-6 antagonists and uses thereof | |
PE20040947A1 (es) | MOLECULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA | |
PE20121646A1 (es) | Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica | |
CO6311009A2 (es) | Anticuerpos monoclonales anti-cd151 de origen murino quimericos y humanizados para inhibir el crecimiento tumoral, secuencias de aminoacidos y nucleicos que los codifican, compuestod derivados o fragmentos funcionales y productos y/o composiciones qu | |
PE20211709A1 (es) | Anticuerpos que reconocen tau |